Provided by Tiger Trade Technology Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

0.4775
-0.0275-5.45%
Post-market: 0.4652-0.0123-2.58%16:38 EST
Volume:47.32K
Turnover:22.79K
Market Cap:1.65M
PE:-0.03
High:0.5200
Open:0.5140
Low:0.4649
Close:0.5050
52wk High:24.80
52wk Low:0.4649
Shares:3.45M
Float Shares:3.42M
Volume Ratio:1.66
T/O Rate:1.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.3057
EPS(LYR):-95.1334
ROE:-361.83%
ROA:-109.63%
PB:1.01
PE(LYR):-0.01

Loading ...

Calidi Biotherapeutics Q3 EPS $(1.47) Up From $(35.25) YoY

Benzinga Earnings
·
Nov 14

Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
Nov 14

Calidi Biotherapeutics Q3 2026 Net Loss Attributable to Common Stockholders Narrows 67% to $3.6 Million

Reuters
·
Nov 14

Calidi's CLD-401 Eradicates Tumors in 80% of Mice in Preclinical Breast Cancer Study

Reuters
·
Oct 27

Calidi Biotherapeutics Publishes Presentation on CLD-401 Tumor Regression in Mouse Models

Reuters
·
Oct 27

Calidi's CLD-401 Shows High Rates of Complete Tumor Eradication in Mice

Reuters
·
Oct 19

Calidi prices 1.025M shares at $1.17 in registered direct offering

TIPRANKS
·
Sep 17

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

THOMSON REUTERS
·
Sep 17

Calidi Biotherapeutics to Participate in H.C. Wainwright Annual Global Investment Conference

Reuters
·
Sep 08

Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY

Benzinga Earnings
·
Aug 14

Calidi Biotherapeutics Q2 FY26 Net Loss Narrows 26.32% to $4.2 Million; General and Administrative Expense Drops 48% to $1.6 Million

Reuters
·
Aug 14

Calidi Biotherapeutics - Reports Q2 Net Loss of $4.20 Mln, or $2.94 Per Share

THOMSON REUTERS
·
Aug 14

Press Release: Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Dow Jones
·
Aug 14

Calidi Biotherapeutics Effects 1-for-16 Reverse Stock Split

Reuters
·
Aug 01

Calidi Biotherapeutics Targets Q1 2027 Clinic Entry for Cld-401 Cancer Program

Reuters
·
Jul 27

Calidi Biotherapeutics Provides Mid-year Corporate Update and Future Key Value Drivers

THOMSON REUTERS
·
Jul 21

Calidi Biotherapeutics - Reduces G&a Expenses by $1 Mln from Q1 2025 to Q1 2026

THOMSON REUTERS
·
Jul 21

Calidi Biotherapeutics - Targets First Patient Dosing in Cld-401 Phase I Trial in Q1 2027

THOMSON REUTERS
·
Jul 21

Calidi Biotherapeutics Announces 1-for-16 Reverse Stock Split Effective July 31

Reuters
·
Jul 21

Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026

THOMSON REUTERS
·
Jul 21